Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Open-label, National, Multicenter Study Evaluating the Efficacy and Safety of the Combination of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in Hepatocellular Carcinoma (ASPIRE)

NCT07018947 is registered in ClinicalTrials.gov with Fundacion Clinic per a la Recerca Biomédica as lead sponsor.

NCT NCT07018947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07018947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Open-label, National, Multicenter Study Evaluating the Efficacy and Safety of the Combination of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in Hepatocellular Carcinoma (ASPIRE)
Lead sponsor
Fundacion Clinic per a la Recerca Biomédica
Phase
Phase 2
Overall status
Recruiting
Start date
June 2, 2026
Completion date
June 30, 2031
Enrollment
90 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

resectable hepatocellular carcinoma